Evidence map›Paper›PMID 31180122›Full record

ArticleNeuro-oncology2019

Sustained imaging response and hearing preservation with low-dose bevacizumab in sporadic vestibular schwannoma.

Matthias A Karajannis, Mari Hagiwara, Mark Schreyer, Sofia Haque

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in Neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Molecular predictors of recurrence in vestibular schwannomas: a transcriptomic and RT-qPCR analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Article
  3. Review
  4. Article
  5. [Prospects of Drug Therapy of Vestibular Schwannoma].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2022
    Review
  6. A Critical Overview of Targeted Therapies for Vestibular Schwannoma.International journal of molecular sciences · 2022
    Review
  7. A Review of Drug Therapy in Vestibular Schwannoma.Drug design, development and therapy · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Matthias A KarajannisPediatric Neuro-Oncology Service, Department of Pediatrics, Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York.
Mari HagiwaraDepartment of Radiology, NYU Langone Health, New York, New York.
Mark SchreyerDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Sofia HaqueDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Memorial Sloan Kettering Cancer Center · USNYU Langone Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Agents, ImmunologicalBevacizumabFemaleHearing LossHumansMagnetic Resonance ImagingMiddle AgedNeuroma, AcousticPrognosisAntineoplastic Agents, ImmunologicalBevacizumabbevacizumabhearing lossvestibular schwannoma

Identifiers

PMID31180122
PMCPMC6556842
OpenAlexW2941691447

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.